Factor VIII inhibitor and bronchogenic carcinoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Acquired factor VIII inhibitors are rare autoimmune disorders.
• Bronchogenic carcinoma is a common malignancy with various paraneoplastic syndromes.
• Coagulation factor inhibitors can lead to significant bleeding complications.

Observation:

• A patient presented with a newly developed inhibitor to procoagulant factor VIII (FVIIIC) three years post-resection of bronchogenic carcinoma.
• The inhibitor demonstrated specific activity patterns, lacking ristocetin cofactor activity but showing potential activity against factor XI.
• The patient's condition improved following immunosuppressive therapy.

Findings:

• This case represents the first reported association between bronchogenic carcinoma and the development of a factor VIII inhibitor.
• The inhibitor's specific activity profile provides insights into its potential targets and mechanisms.
• Successful immunosuppressive treatment highlights a viable therapeutic strategy for such rare conditions.

Implications:

• The findings suggest that certain malignancies, like bronchogenic carcinoma, may trigger autoimmune responses leading to factor VIII inhibitors.
• This association broadens the understanding of paraneoplastic syndromes.
• Early recognition and immunosuppressive therapy are crucial for managing patients with cancer-associated factor VIII inhibitors.